Spots Global Cancer Trial Database for First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
Official Title: A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)
Study ID: NCT01669226
Study Description
Brief Summary: The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.
Detailed Description: This exploratory trial is to compare the efficacy of sequential chemotherapy, intraperitoneal chemotherapy followed by intravenous chemotherapy, versus intravenous chemotherapy alone in the first-line therapy for ovarian cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
Suzhou Municipal Hospital, Suzhou, Jiangsu, China
Wuxi Cancer Hospital, Wuxi, Jiangsu, China
Shanghai Zhongshan Hospital, Shanghai, Shanghai, China
Ren Ji Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
Shanghai Frist Maternity and Infant Hospital Affiliated to Tongji University, Shanghai, Shanghai, China
Fudan University Cancer Hospital, Shanghai, , China
Contact Details
Name: Rongyu Zang, MD,PhD
Affiliation: Shanghai Gynecologic Oncology Group
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
